Erik P Sulman

List of Publications by Year
in descending order

197 papers	22,967 citations	22153 59 h-index	8866 145 g-index
208 all docs	208 docs citations	208 times ranked	28435 citing authors

#	Article	IF	Citations
1	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. Clinical Cancer Research, 2022, 28, 594-602.	7.0	67
2	Update on Radiation Therapy for Central Nervous System Tumors. Hematology/Oncology Clinics of North America, 2022, 36, 77-93.	2.2	5
3	Stereotactic radiosurgery for glioblastoma considering tumor genetic profiles: an international multicenter study. Journal of Neurosurgery, 2022, 137, 42-50.	1.6	4
4	Genetic modulation of longitudinal change in neurocognitive function among adult glioma patients. Journal of Neuro-Oncology, 2022, 156, 185-193.	2.9	2
5	Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. Journal of Clinical Oncology, 2022, 40, 492-516.	1.6	261
6	Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. Neuro-Oncology, 2022, 24, 331-357.	1.2	4
7	Risk of Second Primary Neoplasms of the Central Nervous System. Advances in Radiation Oncology, 2022, 7, 100969.	1.2	1
8	Evaluation of <i>in vitro</i> and <i>in vivo</i> efficacy of pharmacological lysine‐specific demethylase 1 (LSD1) inhibitors in glioblastoma stem cell (GSC) models. FASEB Journal, 2022, 36, .	0.5	0
9	Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline. Journal of Clinical Oncology, 2022, 40, 2271-2276.	1.6	27
10	Significant survival improvements for patients with melanoma brain metastases: can we reach cure in the current era?. Journal of Neuro-Oncology, 2022, 158, 471-480.	2.9	5
11	Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons. Neuro-Oncology, 2021, 23, 284-294.	1.2	78
12	Breaking Tradition to Bridge Bench and Bedside: Accelerating the MD-PhD-Residency Pathway. Academic Medicine, 2021, 96, 518-521.	1.6	2
13	The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment. Neuro-Oncology Advances, 2021, 3, vdab035.	0.7	3
14	A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma. Neuro-Oncology, 2021, 23, 1337-1347.	1.2	50
15	PRMT6 methylation of RCC1 regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells. Molecular Cell, 2021, 81, 1276-1291.e9.	9.7	54
16	Abstract PO-019: Radiotherapy in cancer is associated with a deletion signature that contributes to poor patient outcomes. , 2021, , .		0
17	Medium-Chain Acyl-CoA Dehydrogenase Protects Mitochondria from Lipid Peroxidation in Glioblastoma. Cancer Discovery, 2021, 11, 2904-2923.	9.4	23
18	Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer. Nature Genetics, 2021, 53, 1088-1096.	21.4	94

#	Article	IF	Citations
19	Loss of H3K27me3 in meningiomas. Neuro-Oncology, 2021, 23, 1282-1291.	1.2	45
20	World Cancer Day 2021 - Perspectives in Pediatric and Adult Neuro-Oncology. Frontiers in Oncology, 2021, 11, 659800.	2.8	6
21	A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated *MGMT* glioblastoma: the VERTU study. Neuro-Oncology, 2021, 23, 1736-1749.	1.2	44
22	Phase II Trial of Proton Therapy vs. Photon IMRT for GBM: Secondary Analysis Comparison of Progression Free Survival between RANO vs. Clinical Assessment. Neuro-Oncology Advances, 2021, 3, vdab073.	0.7	1
23	Insight into the public's interest in tumour treating fields. British Journal of Cancer, 2021, 125, 901-903.	6.4	1
24	Hippocampal sparing in patients receiving radiosurgery for ≥25 brain metastases. Radiotherapy and Oncology, 2021, 161, 65-71.	0.6	3
25	Intrinsic Interferon Signaling Regulates the Cell Death and Mesenchymal Phenotype of Glioblastoma Stem Cells. Cancers, 2021, 13, 5284.	3.7	14
26	Stereotactic radiosurgery for IDH wild type glioblastoma: an international, multicenter study. Journal of Neuro-Oncology, 2021, 155, 343-351.	2.9	4
27	*EGFR* Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma. Clinical Cancer Research, 2020, 26, 1395-1407.	7.0	26
28	Full automation of spinal stereotactic radiosurgery and stereotactic body radiation therapy treatment planning using Varian Eclipse scripting. Journal of Applied Clinical Medical Physics, 2020, 21, 122-131.	1.9	5
29	Transcriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastoma. Genome Biology, 2020, 21, 216.	8.8	73
30	Correlative study of epigenetic regulation of tumor microenvironment in spindle cell melanomas and cutaneous malignant peripheral nerve sheath tumors. Scientific Reports, 2020, 10, 12996.	3.3	6
31	Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. Genome Biology, 2020, 21, 271.	8.8	36
32	A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities. Nature Communications, 2020, 11, 2935.	12.8	57
33	Stereotactic Radiation for Treating Primary and Metastatic Neoplasms of the Spinal Cord. Frontiers in Oncology, 2020, 10, 907.	2.8	5
34	Radiation with STAT3 Blockade Triggers Dendritic Cell–T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy. Clinical Cancer Research, 2020, 26, 4983-4994.	7.0	38
35	Genetic driver mutations introduced in identical cell-of-origin in murine glioblastoma reveal distinct immune landscapes but similar response to checkpoint blockade. Glia, 2020, 68, 2148-2166.	4.9	28
36	Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma. Clinical Cancer Research, 2020, 26, 1094-1104.	7.0	124

#	ARTICLE	IF	CITATIONS
37	Novel Therapies for Glioblastoma. Current Neurology and Neuroscience Reports, 2020, 20, 19.	4.2	50
38	EPCO-11. IN VIVO FUNCTIONAL GENOMIC SCREEN IDENTIFIES WISP1 AS AN OVEREXPRESSED DRIVER OF GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii71-ii71.	1.2	0
39	The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma. Journal of the National Cancer Institute, 2019, 111, 292-300.	6.3	32
40	Spatial Distance Correlates With Genetic Distance in Diffuse Glioma. Frontiers in Oncology, 2019, 9, 676.	2.8	8
41	Molecular profiling of long-term IDH-wildtype glioblastoma survivors. Neuro-Oncology, 2019, 21, 1458-1469.	1.2	47
42	MLTI-01. IMMUNOLOGICAL REPROGRAMMING IN THE CNS TUMOR MICROENVIRONMENT AND THERAPEUTIC EFFICACY OF RADIOTHERAPY WITH STAT3 BLOCKADE. Neuro-Oncology Advances, 2019, 1, i14-i14.	0.7	0
43	RADI-27. ROLE OF STEREOTACTIC RADIOSURGERY IN THE CARE OF PATIENTS WITH >/= 25 CUMULATIVE BRAIN METASTASES. Neuro-Oncology Advances, 2019, 1, i27-i27.	0.7	0
44	BSCI-12. COMPREHENSIVE GENOMIC ANALYSIS OF BRAIN METASTASES FROM MULTIPLE CANCER TYPES. Neuro-Oncology Advances, 2019, 1, i3-i3.	0.7	0
45	Identification of patient-derived glioblastoma stem cell (GSC) lines with the alternative lengthening of telomeres phenotype. Acta Neuropathologica Communications, 2019, 7, 76.	5.2	8
46	Differences in patterns of care and outcomes between grade II and grade III molecularly defined 1p19q co-deleted gliomas. Clinical and Translational Radiation Oncology, 2019, 15, 46-52.	1.7	9
47	High‐Throughput Automated Single‐Cell Imaging Analysis Reveals Dynamics of Glioblastoma Stem Cell Population During State Transition. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2019, 95, 290-301.	1.5	12
48	A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma. Scientific Reports, 2019, 9, 1322.	3.3	62
49	G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma. Nature Communications, 2019, 10, 943.	12.8	132
50	Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair. Cancer Cell, 2019, 35, 504-518.e7.	16.8	102
51	Phenotypic Plasticity of Invasive Edge Glioma Stem-like Cells in Response to Ionizing Radiation. Cell Reports, 2019, 26, 1893-1905.e7.	6.4	161
52	ACTR-34. SINGLE AGENT ONC201 IN PREVIOUSLY-TREATED, PROGRESSIVE ADULT H3 K27M-MUTANT GLIOMA. Neuro-Oncology, 2019, 21, vi20-vi21.	1.2	1
53	NIMG-03. PROSPECTIVE PHASE II RANDOMIZED TRIAL COMPARING PROTON THERAPY VS. PHOTON IMRT FOR GBM: SECONDARY ANALYSIS COMPARISON OF PROGRESSION FREE SURVIVAL BETWEEN RANO VS. CLINICAL AND RADIOLOGICAL ASSESSMENT. Neuro-Oncology, 2019, 21, vi161-vi162.	1.2	0
54	ATIM-37. PHASE II, OPEN-LABEL, SINGLE ARM, MULTICENTER STUDY OF AVELUMAB WITH HYPOFRACTIONATED RADIATION (HFRT) FOR ADULT PATIENTS WITH SECONDARILY TRANSFORMED IDH-MUTANT GLIOBLASTOMA (GBM). Neuro-Oncology, 2019, 21, vi9-vi10.	1.2	3

#	Article	IF	Citations
55	RTHP-18. PROSPECTIVE PHASE II RANDOMIZED TRIAL COMPARING PROTON THERAPY VS. PHOTON IMRT FOR NEWLY DIAGNOSED GBM: SECONDARY ANALYSIS COMPARISON OF GENDER AND NEUTROPHIL-LYMPHOCYTE RATIO (NLR) IN GBM OUTCOMES. Neuro-Oncology, 2019, 21, vi213-vi213.	1.2	0
56	RTHP-23. PROSPECTIVE TRIAL OF CONVENTIONALLY FRACTIONATED DOSE CONSTRAINTS FOR RE-IRRADIATION OF PRIMARY BRAIN TUMORS. Neuro-Oncology, 2019, 21, vi214-vi214.	1.2	0
57	DDIS-32. MEK INHIBITORS INDUCES NEURONAL DIFFERENTIATION IN EGFR AMPLIFIED GLIOMA STEM LIKE CELLS. Neuro-Oncology, 2019, 21, vi70-vi70.	1.2	0
58	ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM). Neuro-Oncology, 2019, 21, vi17-vi17.	1.2	23
59	Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers. Scientific Reports, 2019, 9, 16830.	3.3	29
60	Aberrant DNA Methylation Predicts Melanoma-Specific Survival in Patients with Acral Melanoma. Cancers, 2019, 11, 2031.	3.7	23
61	ACTR-24. A RANDOMIZED PHASE II TRIAL OF VELIPARIB (V), RADIOTHERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS (PTS) WITH UNMETHYLATED MGMT (uMGMT) GLIOBLASTOMA (GBM): THE VERTU STUDY. Neuro-Oncology, 2019, 21, vi18-vi18.	1.2	1
62	Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma. Clinical Cancer Research, 2019, 25, 1261-1271.	7.0	50
63	*MIR93* (*microRNA -93*) regulates tumorigenicity and therapy response of glioblastoma by targeting autophagy. Autophagy, 2019, 15, 1100-1111.	9.1	100
64	Phase 1 lead‐in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. Cancer, 2019, 125, 424-433.	4.1	46
65	BCAT1 and miR-2504: novel methylome signature distinguishes spindle/desmoplastic melanoma from superficial malignant peripheral nerve sheath tumor. Modern Pathology, 2019, 32, 338-345.	5.5	8
66	ATRX protein loss and deregulation of PI3K/AKT pathway is frequent in pilocytic astrocytoma with anaplastic features. , 2019, 38, 59-73.		12
67	Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. Neuro-Oncology, 2018, 20, 873-884.	1.2	119
68	Large Scale Identification of Variant Proteins in Glioma Stem Cells. ACS Chemical Neuroscience, 2018, 9, 73-79.	3.5	12
69	Dexamethasone-mediated oncogenicity in vitro and in an animal model of glioblastoma. Journal of Neurosurgery, 2018, 129, 1446-1455.	1.6	22
70	Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling. Nature Communications, 2018, 9, 1057.	12.8	66
71	Ionizing radiation augments glioma tropism of mesenchymal stem cells. Journal of Neurosurgery, 2018, 128, 287-295.	1.6	34
72	MerTK as a therapeutic target in glioblastoma. Neuro-Oncology, 2018, 20, 92-102.	1.2	62

#	ARTICLE	IF	CITATIONS
73	Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha. Neuro-Oncology, 2018, 20, 192-202.	1.2	52
74	Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes. OncoImmunology, 2018, 7, e1412909.	4.6	247
75	Melanoma brain metastases harboring BRAF V600K or NRAS mutations are associated with an increased local failure rate following conventional therapy. Journal of Neuro-Oncology, 2018, 137, 67-75.	2.9	17
76	Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 2386-2394.	1.6	276
77	ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts. PLoS ONE, 2018, 13, e0202860.	2.5	28
78	A Coclinical Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft Models. Clinical Cancer Research, 2018, 24, 6288-6299.	7.0	74
79	The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells. Oncotarget, 2018, 9, 10497-10509.	1.8	18
80	A gene expression signature predicts recurrence-free survival in meningioma. Oncotarget, 2018, 9, 16087-16098.	1.8	26
81	Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. Neuro-Oncology, 2017, 19, now257.	1.2	80
82	Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival. Neuro-Oncology, 2017, 19, now239.	1.2	39
83	An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. Neuro-Oncology, 2017, 19, now208.	1.2	109
84	Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma. Acta Neuropathologica, 2017, 133, 431-444.	7.7	155
85	Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. Journal of Oncology Practice, 2017, 13, 123-127.	2.5	18
86	Retrospective Analysis of Molecular and Immunohistochemical Characterization of 381 Primary Brain Tumors. Journal of Neuropathology and Experimental Neurology, 2017, 76, 179-188.	1.7	23
87	m 6 A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program. Cancer Cell, 2017, 31, 591-606.e6.	16.8	1,131
88	Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma. Neuro-Oncology, 2017, 19, 1469-1480.	1.2	42
89	Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. Journal of Clinical Oncology, 2017, 35, 361-369.	1.6	109
90	PAF promotes stemness and radioresistance of glioma stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E9086-E9095.	7.1	40

#	Article	IF	Citations
91	Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiotherapy and Oncology, 2017, 125, 80-88.	0.6	58
92	A Dexamethasone-regulated Gene Signature Is Prognostic for Poor Survival in Glioblastoma Patients. Journal of Neurosurgical Anesthesiology, 2017, 29, 46-58.	1.2	28
93	MST4 Phosphorylation of ATG4B Regulates Autophagic Activity, Tumorigenicity, and Radioresistance in Glioblastoma. Cancer Cell, 2017, 32, 840-855.e8.	16.8	188
94	GPR56/ADGRG1 Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma. Cell Reports, 2017, 21, 2183-2197.	6.4	56
95	Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell, 2017, 32, 42-56.e6.	16.8	1,282
96	Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1040-1048.	10.7	537
97	Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas. Clinical Cancer Research, 2017, 23, 6215-6226.	7.0	53
98	DRES-04. DEVELOPMENT OF AÂCRISPR-CAS9D10A TARGETABLE, HIGH-COMPLEXITY, SINGLE-CELL BARCODING APPROACH FOR ISOLATION OF TREATMENT RESISTANT SUBCLONES FROM HETEROGENOUS MALIGNANT GLIOMAS. Neuro-Oncology, 2017, 19, vi64-vi64.	1.2	0
99	GENE-36. ACCURATE DETECTION OF TERT PROMOTER MUTATION IN GLIOMAS USING INFINIUM DNA METHYLATION ARRAYS IDENTIFIES NOVEL EPIGENETIC ASSOCIATION. Neuro-Oncology, 2017, 19, vi100-vi100.	1.2	0
100	Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma. Oncotarget, 2017, 8, 21741-21753.	1.8	16
101	Abstract 3348: UniD: unified and integrated diagnostic pipeline for malignant gliomas based on DNA methylation data. , 2017, , .		4
102	APOBEC3G acts as a therapeutic target in mesenchymal gliomas by sensitizing cells to radiation-induced cell death. Oncotarget, 2017, 8, 54285-54296.	1.8	15
103	CDK4/6 inhibition is more active against the glioblastoma proneural subtype. Oncotarget, 2017, 8, 55319-55331.	1.8	39
104	A relative increase in circulating platelets following chemoradiation predicts for poor survival of patients with glioblastoma. Oncotarget, 2017, 8, 90488-90495.	1.8	13
105	Identification of Histological Correlates of Overall Survival in Lower Grade Gliomas Using a Bag-of-words Paradigm: A Preliminary Analysis Based on Hematoxylin & Eosin Stained Slides from the Lower Grade Glioma Cohort of The Cancer Genome Atlas. Journal of Pathology Informatics, 2017, 8, 9.	1.7	17
106	Comprehensive molecular and immune profiling of non-small cell lung cancer and matched distant metastases to suggest distinct molecular mechanisms underlying metastasis.. Journal of Clinical Oncology, 2017, 35, 8541-8541.	1.6	0
107	Relative thrombocytosis following chemoradiation of patients with glioblastoma to predict survival.. Journal of Clinical Oncology, 2017, 35, e13527-e13527.	1.6	0
108	Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight, 2016, 1, .	5.0	356

#	Article	IF	Citations
109	Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth. Cell, 2016, 167, 1281-1295.e18.	28.9	207
110	TIE2-mediated tyrosine phosphorylation of H4 regulates DNA damage response by recruiting ABL1. Science Advances, 2016, 2, e1501290.	10.3	33
111	A regulatory circuit of miR-125b/miR-20b and Wnt signalling controls glioblastoma phenotypes through FZD6-modulated pathways. Nature Communications, 2016, 7, 12885.	12.8	72
112	139â€ƒClinically Applicable and Biologically Validated MRI Radiomic Test Method Predicts Glioblastoma Genomic Landscape and Survival. Neurosurgery, 2016, 63, 156-157.	1.1	14
113	TMIC-14. TUMOR EVOLUTION OF GLIOMA INTRINSIC GENE EXPRESSION SUBTYPE ASSOCIATES WITH IMMUNOLOGICAL CHANGES IN THE MICROENVIRONMENT. Neuro-Oncology, 2016, 18, vi202-vi202.	1.2	11
114	Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells. Journal of Translational Medicine, 2016, 14, 46.	4.4	31
115	Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in an NF-κB-dependent Manner. Cancer Cell, 2016, 29, 201-213.	16.8	147
116	TERT Promoter Mutations and Risk of Recurrence in Meningioma. Journal of the National Cancer Institute, 2016, 108, djv377.	6.3	283
117	Polymorphisms risk modeling for vascular toxicity in patients with glioblastoma treated on NRG Oncology/RTOG 0825.. Journal of Clinical Oncology, 2016, 34, 2049-2049.	1.6	1
118	An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG oncology/RTOG 0525 and 0825.. Journal of Clinical Oncology, 2016, 34, 2007-2007.	1.6	0
119	Abstract 1646: A glioblastoma methylation assay (GaMA) developedfrom genomic analysis of glioma spheroid cultures predicts response toradiation therapy in patients with glioblastoma. , 2016, , .		0
120	Abstract 4217: First pre-clinical validation of radiogenomics in glioblastoma. , 2016, , .		0
121	Abstract 1505: Radiogenomics defines key genomic network driving GBM invasion. , 2016, , .		0
122	EPIG-05RADIORESISTANCE OF PODOPLANIN-EXPRESSING GLIOMA STEM CELLS IS ASSOCIATED WITH EZH2-DRIVEN POLYCOMB REPRESSIVE COMPLEX ACTIVITY. Neuro-Oncology, 2015, 17, v87.1-v87.	1.2	0
123	The proteomic landscape of glioma stem-like cells. EuPA Open Proteomics, 2015, 8, 85-93.	2.5	11
124	MTR-19A MACROPHAGE-/MICROGLIAL-RICH TUMOR MICROENVIRONMENT MIMICS PRONEURAL TO MESENCHYMAL TRANSITION IN GLIOBLASTOMA. Neuro-Oncology, 2015, 17, v128.3-v128.	1.2	0
125	Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases. Journal of Clinical Oncology, 2015, 33, 2239-2245.	1.6	104
126	GENO-36GLIOMA SPHERE-FORMING CELLS REVEAL INTRINSIC GLOBAL HYPERMETHYLATION ASSOCIATED WITH GBM RADIATION RESISTANCE. Neuro-Oncology, 2015, 17, v99.5-v100.	1.2	0

#	ARTICLE	IF	CITATIONS
127	Mir-21â€"Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact. Journal of Neuroscience, 2015, 35, 15097-15112.	3.6	53
128	EZH2 Protects Glioma Stem Cells from Radiation-Induced Cell Death in a MELK/FOXM1-Dependent Manner. Stem Cell Reports, 2015, 4, 226-238.	4.8	159
129	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. New England Journal of Medicine, 2015, 372, 2481-2498.	27.0	2,582
130	IDH mutation status and role of WHO grade and mitotic index in overall survival in grade IIâ€"III diffuse gliomas. Acta Neuropathologica, 2015, 129, 585-596.	7.7	272
131	Genetic Modulation of Neurocognitive Function in Glioma Patients. Clinical Cancer Research, 2015, 21, 3340-3346.	7.0	29
132	Molecular Markers in Low-Grade Gliomaâ€"Toward Tumor Reclassification. Seminars in Radiation Oncology, 2015, 25, 155-163.	2.2	62
133	Antiepileptic drug use improves overall survival in breast cancer patients with brain metastases in the setting of whole brain radiotherapy. Radiotherapy and Oncology, 2015, 117, 308-314.	0.6	23
134	Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway. Stem Cells, 2015, 33, 2400-2415.	3.2	163
135	Delineation of<i>MGMT</i>Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. Journal of the National Cancer Institute, 2015, 108, djv369.	6.3	102
136	Systematic Identification of Single Amino Acid Variants in Glioma Stem-Cell-Derived Chromosome 19 Proteins. Journal of Proteome Research, 2015, 14, 778-786.	3.7	22
137	Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastoma. Oncogene, 2015, 34, 1619-1628.	5.9	82
138	Use of ENCODE Resources to Characterize Novel Proteoforms and Missing Proteins in the Human Proteome. Journal of Proteome Research, 2015, 14, 603-608.	3.7	17
139	Mitotic Index is an Independent Predictor of Recurrenceâ€"Free Survival in Meningioma. Brain Pathology, 2015, 25, 266-275.	4.1	97
140	Aberrant mesenchymal differentiation of glioma stem-like cells: implications for therapeutic targeting. Oncotarget, 2015, 6, 31007-31017.	1.8	24
141	Abstract 532: Circulating myeloid precursor profile as potential marker to differentiate radiation changes from tumor recurrence after brain stereotactic radiosurgery. , 2015, , .		0
142	Abstract 3483: Synergistic combination therapy with molecular targeted drugs in glioma stem-like cells. , 2015, , .		0
143	Abstract 3298: ABL1 is required for Tie2-mediated DNA repair in brain tumor stem cells. , 2015, , .		0
144	Abstract 4795: A novel gene fusion in glioblastoma and a radiation response methylation signature identified by genomic characterization of glioma sphere-forming cells. , 2015, , .		0

#	Article	IF	Citations
145	Abstract 695: Synergistic antitumor effects of polo like kinase inhibitor volasertib in combination with ionizing radiation in glioblastoma. , 2015, , .		0
146	Bevacizumab for Newly Diagnosed Glioblastoma. New England Journal of Medicine, 2014, 370, 2048-2049.	27.0	98
147	IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro-Oncology, 2014, 16, 81-91.	1.2	370
148	A High Notch Pathway Activation Predicts Response to Î³ Secretase Inhibitors in Proneural Subtype of Glioma Tumor-Initiating Cells. Stem Cells, 2014, 32, 301-312.	3.2	117
149	A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma. New England Journal of Medicine, 2014, 370, 699-708.	27.0	2,279
150	Integrated Chromosome 19 Transcriptomic and Proteomic Data Sets Derived from Glioma Cancer Stem-Cell Lines. Journal of Proteome Research, 2014, 13, 191-199.	3.7	27
151	Dosimetric Predictors of Duodenal Toxicity After Intensity Modulated Radiation Therapy for Treatment of the Para-aortic Nodes in Gynecologic Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 88, 357-362.	0.8	62
152	Abstract 3944: Caveolin-mediated Tie2 nuclear translocation results in enhanced NHEJ repair and glioma radioresistance. , 2014, , .		1
153	Mesenchymal high-grade glioma is maintained by the ID-RAP1 axis. Journal of Clinical Investigation, 2014, 124, 4134-4134.	8.2	2
154	Chromosome 19 Annotations with Disease Speciation: A First Report from the Global Research Consortium. Journal of Proteome Research, 2013, 12, 135-150.	3.7	16
155	Galectin-7 levels predict radiation response in squamous cell carcinoma of the cervix. Gynecologic Oncology, 2013, 131, 645-649.	1.4	22
156	Acquired Resistance to Anti-VEGF Therapy in Glioblastoma Is Associated with a Mesenchymal Transition. Clinical Cancer Research, 2013, 19, 4392-4403.	7.0	164
157	Mesenchymal Differentiation Mediated by NF-κB Promotes Radiation Resistance in Glioblastoma. Cancer Cell, 2013, 24, 331-346.	16.8	856
158	Predictors of Survival in Contemporary Practice After Initial Radiosurgery for Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2013, 85, 656-661.	0.8	98
159	Tumor Prognostic Factors and the Challenge of Developing Predictive Factors. Current Oncology Reports, 2013, 15, 33-46.	4.0	1
160	Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Nonâ€"Small-Cell Lung Cancer. Journal of Clinical Oncology, 2013, 31, 895-902.	1.6	366
161	Novel HSP90 Inhibitor NVP-HSP990 Targets Cell-Cycle Regulators to Ablate Olig2-Positive Glioma Tumorâ€"Initiating Cells. Cancer Research, 2013, 73, 3062-3074.	0.9	21
162	A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. Genes and Development, 2013, 27, 1462-1472.	5.9	74

#	Article	IF	Citations
163	Mesenchymal high-grade glioma is maintained by the ID-RAP1 axis. Journal of Clinical Investigation, 2013, 123, 405-417.	8.2	70
164	Abstract A110: EGFRvIII expression is associated with shorter progression-free and overall survival in glioblastoma patients treated with standard-of-care temozolomide and radiation: A report from the RTOG-0525 trial.. , 2013, , .		0
165	Molecular biology of brain tumors. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 104, 23-34.	1.8	11
166	Histone Deacetylase Inhibitors Stimulate Dedifferentiation of Human Breast Cancer Cells Through WNT/Î²â€Catenin Signaling. Stem Cells, 2012, 30, 2366-2377.	3.2	100
167	Management of Brain Metastasis: Past Lessons, Modern Management, and Future Considerations. Current Oncology Reports, 2012, 14, 70-78.	4.0	27
168	Validation of Recursive Partitioning Analysis and Diagnosis-Specific Graded Prognostic Assessment in patients treated initially with radiosurgery alone. Journal of Neurosurgery, 2012, 117, 38-44.	1.6	31
169	The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes and Development, 2011, 25, 2594-2609.	5.9	326
170	Multigene Sets for Clinical Application in Glioma. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 449-457.	4.9	6
171	The Use of Global Profiling in Biomarker Development for Gliomas. Brain Pathology, 2011, 21, 88-95.	4.1	19
172	Tumor Profiling: Development of Prognostic and Predictive Factors to Guide Brain Tumor Treatment. Current Oncology Reports, 2011, 13, 26-36.	4.0	5
173	Discovering functional modules by identifying recurrent and mutually exclusive mutational patterns in tumors. BMC Medical Genomics, 2011, 4, 34.	1.5	119
174	Bayesian ensemble methods for survival prediction in gene expression data. Bioinformatics, 2011, 27, 359-367.	4.1	56
175	Abstract 2467: Podoplanin expressing cancer stem cells show increased resistance to DNA damage induced by ionizing radiation. , 2011, , .		0
176	Bagged gene shaving for the robust clustering of high-throughput data. International Journal of Bioinformatics Research and Applications, 2010, 6, 326.	0.2	4
177	Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma. Cancer Cell, 2010, 17, 510-522.	16.8	2,078
178	The transcriptional network for mesenchymal transformation of brain tumours. Nature, 2010, 463, 318-325.	27.8	1,114
179	A multigene predictor of outcome in glioblastoma. Neuro-Oncology, 2010, 12, 49-57.	1.2	334
180	MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro-Oncology, 2010, 12, 116-121.	1.2	316

#	Article	IF	Citations
181	Beyond Grade: Molecular Pathology of Malignant Gliomas. Seminars in Radiation Oncology, 2009, 19, 142-149.	2.2	31
182	Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer. Radiation Oncology, 2009, 4, 5.	2.7	59
183	IMRT Reirradiation of Head and Neck Cancerâ€"Disease Control and Morbidity Outcomes. International Journal of Radiation Oncology Biology Physics, 2009, 73, 399-409.	0.8	218
184	Transcription Profiling of Brain Tumors: Tumor Biology and Treatment Stratification. , 2009, , 529-551.		2
185	Prognostic and Predictive Markers in Glioma and Other Neuroepithelial Tumors. Current Problems in Cancer, 2008, 32, 97-123.	2.0	16
186	Brain Tumor Stem Cells. Current Problems in Cancer, 2008, 32, 124-142.	2.0	22
187	Cancer stem cells: markers or biomarkers?. Cancer and Metastasis Reviews, 2008, 27, 459-470.	5.9	102
188	Epidermal Growth Factor Receptor Variant III Status Defines Clinically Distinct Subtypes of Glioblastoma. Journal of Clinical Oncology, 2007, 25, 2288-2294.	1.6	260
189	Genomic annotation of the meningioma tumor suppressor locus on chromosome 1p34. Oncogene, 2004, 23, 1014-1020.	5.9	47
190	Identification of a 1-megabase consensus region of deletion at 1p36.3 in primary neuroblastomas. Medical and Pediatric Oncology, 2000, 35, 512-515.	1.0	25
191	Loss of Heterozygosity at 1p36 Independently Predicts for Disease Progression But Not Decreased Overall Survival Probability in Neuroblastoma Patients: A Childrenâ€™s Cancer Group Study. Journal of Clinical Oncology, 2000, 18, 1888-1899.	1.6	146
192	A Comprehensive View of Human Chromosome 1. Genome Research, 1999, 9, 978-988.	5.5	13
193	ECK,a HumanEPH-Related Gene, Maps to 1p36.1, a Common Region of Alteration in Human Cancers. Genomics, 1997, 40, 371-374.	2.9	60
194	An Integrated Transcript Map of Human Chromosome 1p35â€"p36. Genomics, 1997, 42, 126-136.	2.9	36
195	Physical Mapping and Genomic Structure of the HumanTNFR2Gene. Genomics, 1996, 35, 94-100.	2.9	65
196	Cloning, Chromosomal Localization, Physical Mapping, and Genomic Characterization ofHKR3. Genomics, 1996, 35, 289-298.	2.9	18
197	Molecular characterization and chromosomal localization of DRT (EPHT3): a developmentally regulated human protein--tyrosine kinase gene of the EPH family. Human Molecular Genetics, 1995, 4, 2033-2045.	2.9	26